Reports of preliminary talks between AstraZeneca and Bristol Myers Squibb moved shares and reignited debate over Big Pharma ...

Reported Standalone quarterly numbers for AstraZeneca Pharma are: Net Sales at Rs 682.79 crore in June 2026 up 29.73% from Rs. 526.31 crore in June 2025. Quarterly Net Profit at Rs. 37.93 crore in ...

U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AstraZeneca chief Pascal Soriot had repeatedly told investors he did not need a big deal to clinch his $80bn ...

It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company ...

It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired ...

The logic of a pharma megamerger is questionable, but AstraZeneca’s record isn’t.

While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its ...

By Maggie Fick LONDON, Aug 3 (Reuters) - AstraZeneca investors punished the pharmaceutical firm on Monday over reports of ...

By Sabrina Valle and Michael Erman Aug 2 (Reuters) - AstraZeneca Plc and Bristol Myers Squibb held preliminary discussions ...

In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the ...

AstraZeneca and CSPC Pharmaceutical are strengthening their partnership by establishing a new biologics manufacturing joint ...